Research & Reports
Sep 20, 2026•1 min read
Daraxonrasib Demonstrates Tumor Reduction in NSCLC in Early Study
Within a week of U.S. approval for pancreatic cancer, daraxonrasib showed tumor shrinkage in over 30% of non‑small cell lung cancer patients in a small trial.
Research & Reports
Aug 24, 2026•1 min read
Verastem Shifts R&D Focus After Modest Data on Pancreatic Cancer Combo
Verastem Oncology reports modest updated results for its approved first‑line metastatic pancreatic cancer regimen of avutometinib plus defactinib and will redirect primary R&D resources to other pipeline candidates.